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Abstract
Background: Delivery of long-acting nanoformulated antiretroviral drugs (ARVs) to human
immunodeficiency virus type one cell and tissue reservoirs underlies next generation antiretroviral
therapeutics. Nanotheranostics, comprised of trackable nanoparticle adjuncts, can facilitate ARV delivery
through real-time drug tracking made possible through bioimaging platforms.
Methods: To model HIV-1 therapeutic delivery, europium sulfide (EuS) nanoprobes were developed,
characterized and then deployed to cells, tissues, and rodents. Tests were performed with nanoformulated
rilpivirine (NRPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI) used clinically to suppress or
prevent HIV-1 infection. First, CD4+ T cells and monocyte-derived macrophages were EuS-treated with and
without endocytic blockers to identify nanoprobe uptake into cells. Second, Balb/c mice were co-dosed with
NRPV and EuS or lutetium177-doped EuS (177LuEuS) theranostic nanoparticles to assess NRPV biodistribution
via mass spectrometry. Third, single photon emission computed tomography (SPECT-CT) and magnetic
resonance imaging (MRI) bioimaging were used to determine nanotheranostic and NRPV anatomic
redistribution over time.
Results: EuS nanoprobes and NRPV entered cells through dynamin-dependent pathways. SPECT-CT and MRI
identified biodistribution patterns within the reticuloendothelial system for EuS that was coordinate with
NRPV trafficking.
Conclusions: EuS nanoprobes parallel the uptake and biodistribution of NRPV. These data support their use
in modeling NRPV delivery to improve treatment strategies.
Key words: HIV-1, antiretroviral, nanotheranostics, europium, molecular imaging, SPECT-CT

Introduction
Infection by the human immunodeficiency virus
type 1 (HIV-1) requires lifelong daily adherence to
antiretroviral therapy (ART). ART treatment
suppresses viral replication, mitigates transmission,
and delays acquired immunodeficiency syndrome
(AIDS) onset. Lack of access to treatment, negative
social stigma, and drug associated toxicities
contribute to a nearly 41% regimen adherence failure

rate [1, 2]. Indeed, in the absence of ART, HIV-1
replicates continuously in virus target cells. These
include CD4+ T lymphocytes and, to a lesser extent,
mononuclear
phagocytes
(MP;
monocytes,
macrophages, and dendritic cells) promoting either
long-lived cell reservoirs or selective cell death,
respectively. Integration of proviral DNA in cells
perpetuates infection, disease, and viral transmission.
http://www.ntno.org
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The means to improve antiretrovirals that maximally
suppress HIV-1 replication or simplify pre-exposure
prophylaxis (PrEP) drug regimens is of immediate
need for viral therapy and prevention.
Recent
clinical
trials
demonstrate
the
effectiveness of nanoformulated antiretrovirals as
long-acting HIV-1 maintenance and prevention
therapies. These are combinations of long-acting
rilpivirine (RPV), a non-nucleoside reverse
transcriptase inhibitor [3], and the integrase strand
transfer inhibitor (INSTI), cabotegravir (CAB) [4].
Once a month, or once every other month, dosing was
demonstrated to be a non-inferior regimen to daily
oral therapy [3-8]. Similar strategies were recently
developed for other antiretrovirals [9, 10]. Indeed,
encasing these drugs in polymer excipients facilitates
a slow dissolution of drugs from intramuscular
injection sites. Plasma drug levels of protease
inhibitors (PI) ritonavir, indindavir, atazanavir (ATV)
and the NNRTI, efavirenz, were raised 1.5-4 fold
encased in poloxamer 188 excipients [11]. Despite
simplified dosing regimens, suboptimal delivery of
INSTI to lymph nodes [12] and sequestration of
nucleoside reverse transcriptase inhibitors by adipose
tissues [13] prompt concern for low-level viral
replication
in
tissues
despite
maintaining
undetectable levels of the virus in circulation. Thus,
further characterization of antiretroviral nanoparticle
biodistribution is warranted.
Defining delivery for HIV-1 therapeutic agents
to lymphoid tissues could aid in the design of more
effective clinical outcomes. To this end, theranostics
serve as a bridge between therapeutic and diagnostic
tracking. Previous iterations of HIV-1 theranostics
included spherical europium cobalt-ferrite (CFEu)
[14] and bismuth sulfide nanorods (BSNRs) [15].
These particles, loaded with RPV [14, 15] or
dolutegravir (DTG; an INSTI) [16], showed
characteristics of enhanced particle uptake in
macrophages. Real-time non-invasive tracking of
nanoparticles biodistribution using fluorescence,
magnetic resonance imaging (MRI), and single photon
emission
computed
tomography
(SPECT-CT)
conferred by their metal cores or inserting radiolabel
tags have allowed the prediction of drug
biodistribution based on early bioimaging composite
analyses [15].
Taken together, theranostics provide a platform
to construct nanoparticles in pursuit of sustained HIV
suppression, a prerequisite for viral elimination from
organisms [17]. Herein, we tested the concept that
theranostics and antiretroviral nanoparticles with
similar sizes and shapes will display parallel
biodistributions. A novel theranostic agent, europium
sulfide (EuS), was deployed as a cellular uptake
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model. EuS nanoprobes elucidate a potential
dynamin-mediated mechanism for direct nanoparticle
endocytosis by CD4+ T cells, a principal target of
HIV-1. Real-time and non-invasive molecular imaging
also reveals the utility of EuS as companion particles
for NRPV in trafficking nanoparticles to known
reservoir tissues, such as the spleen. These advances
signal how nanotheranostic agents may serve as
surrogates to better design long-acting ART and
clustered regularly interspaced short palindromic
repeats (CRISPR) nanoformulations for therapeutic
delivery and viral elimination.

Methods
Materials
RPV
was
purchased
from
LeapChem
(Hangzhou, China). RPV nanoformulations (NRPV)
were manufactured using an Avestin EmulsiFlex-C3
high-pressure homogenizer (Ottawa, ON, Canada).
NRPV was prepared to replicate RPV LA developed
by Janssen [18], as described previously [19].
UPLC-MS/MS parameters for drug concentration
determinations were performed as reported [19] and
are
detailed
in
supplementary
materials.
L-α-phosphatidylcholine, Tween-80, europium (III)
chloride hexahydrate, 1-dodecanethiol, oleic acid, and
oleylamine were obtained from Sigma-Aldrich.
177LuCl
3 was obtained from the National Isotope
Development Center, Oak Ridge National Laboratory,
Oak Ridge, TN, USA. DSPE-PEG2000 was purchased
from Corden Pharma.

Cells
CEM-ss CD4+ T cells (NIH AIDS Reagent
Program #776) were cultured in RPMI 1640
containing 2 mM L-Glutamine, 10% fetal bovine
serum, and 100 U/mL penicillin plus streptomycin
(PenStrep). Monocytes were obtained from human
HIV-1/2 and hepatitis seronegative donor elutriation
without person identifiers and was thus exempt from
the University of Nebraska Medical Center (UNMC)
Institutional Review Board review. Cells were
differentiated into monocyte-derived macrophages
(MDM) by culture in Dulbecco’s Modified Eagle
Media (DMEM) containing 4.5 g/L glucose, 10%
pooled human serum, 1000 U/mL macrophage
colony-stimulating factor, 1% glutamine, 50 μg/mL
gentamicin, and 10 μg/mL ciprofloxacin for 7 days.

Animals
Male Balb/c mice (8 weeks old) were purchased
from Jackson Laboratories (Bar Harbor, Maine, USA).
Animals were housed in the UNMC Comparative
Medicine animal facility according to the Association
for Assessment and Accreditation of Laboratory
http://www.ntno.org
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Animal Care guidance. The UNMC Institutional
Animal Care and Use Committee approved all
protocols related to animal experiments and were
certified to have met the requirements and ethical
guidelines set forth by the National Institutes of
Health in handling laboratory animals for research.

Synthesis of 177LuEuS particles
Intrinsically radiolabeled 177LuEuS particles,
were prepared by a solvothermal technique in an
isolated radioactive workstation. Europium (III)
chloride hexahydrate (0.2 mM, ~72 mg), oleic acid (0.5
ml), and oleylamine (4 ml) were mixed in a glass vial
and this mixture was stirred for 30 min, and
completely dispersed by bath sonication. Then ~70
mCi of 177LuCl3 and 1-octadecene (5 mL) were mixed
in a separate vial and transferred to the europiumoleic acid-oleylamine (Eu-OA-OAm) mixture.
1-Dodecanethiol (3.0 mL) was quickly added to the
reaction medium. The mixture was sonicated for 15
minutes to provide a completely homogenous
mixture. After vigorous stirring for 10 min, the
solution was transferred into a high safety
Teflon-lined reactor placed in a stainless-steel
autoclave reactor, sealed airtight, and heated at 290°C
for 1 hour. The systems were then allowed to cool
naturally to room temperature (around 8 hours). After
reaching room temperature, the reactor was opened in
a controlled radioisotope workstation. Fifty milliliters
of ethanol were added, vortexed and sonicated. The
solution was then centrifuged at 976 x g for 30
minutes at 15°C. 177LuEuS particles were collected and
purified by repeating the same ethanol washing
process three times to remove non-reacted
components. The radioactive concentration of
gamma-ray emitting lutetium-177 in stock 177LuEuS
was measured using a gamma counter (CRC®-25R
dose calibrator, Capintec, Inc, Florham Park, NJ, USA)
(activity was ~ 60 mCi). Lipid coated 177LuEuS
particles were prepared by thin-film dispersion
technique. First, 100 mg L-α-phosphatidylcholine and
50 mg DSPE-PEG2000 were dissolved in a
chloroform/hexane mixture (5:1 v/v) contained
within a round-bottomed flask and evaporated to
form a thin film using a rotavap (Heidolph, Hei-VAP
Precision; G3B Vertical, USA). The films were dried
under vacuum overnight to complete the removal of
organic solvents. Second, 177LuEuS particles were
dispersed in chloroform (4 mL) followed by bath
sonication for ~ 10 min to get a uniform dispersion of
the particles in the solvent. The 177LuEuS- chloroform
dispersion was mixed with 3 mL of 2% (v/v)
Tween-80 in a 25 mL round-bottom flask and
sonicated for 5 minutes to form a turbid metalosome
emulsion. Third, chloroform was removed from the
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177LuEuS/chloroform/Tween-80

emulsion
by
rotaevaporation. Lastly, the 177LuEuS particle solution
was transferred to the lipid film-coated roundbottomed flask and dispersed in the lipid film
through gentle rotation at 35°C with continuous bath
sonication. Lipid coated 177LuEuS was used for
radioactivity analyses. Non-radiolabeled EuS particles
were synthesized by the same procedure lacking
177LuCl as a reactant.
3

Radiolabeled particle stability
The in vitro stability of lipid coated 177LuEuS
particles was determined by spiking 10.2 μCi (~ 100
μL) of 177LuEuS in tubes containing 400 μL Balb/c
mouse serum incubated at 25°C or 37ºC for seven
days. The samples were centrifuged at 77,474 × g for
30 minutes at 10ºC. The supernatant was collected
into a separate microcentrifuge tube. The radioactivity
in the pellet and the supernatant was measured by
gamma counter. To determine percent stability the
following equation was used: Radiolabeling stability
(%) = radioactivity in pellet/total radioactivity (pellet
plus supernatant) × 100.

Cellular uptake of NRPV and EuS
For CD4+ T cell studies, individual wells of
12-well tissue culture plates were precoated with 100
μg/mL poly-L-lysine for one hour and then the
contents were removed and washed once with sterile
PBS. CEM-ss CD4+ T cells or MDM were seeded in
12-well plates at 1 × 106 cells / well in 1 mL media.
The non-cytotoxic concentration of EuS was
determined by absorbance at 490 nm after cells were
treated with serially diluted EuS for 24 hours,
followed by 2-hour incubation with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT,
1 mg/mL). T cells and MDM received lipid-coated
EuS particle treatments at 10 ppm and 100 ppm of
Eu-153 (Eu153), respectively. Chemical inhibitors were
spiked into appropriate wells at final concentrations
of 30 μM Pitstop2, 100 μM Dynasore, or 4 μM CK666.
At designated time points, supernatants were
discarded, and cells were washed 3× with 1 mL PBS
and counted by trypan blue exclusion staining. After
that, collected contents were centrifuged 650 × g for 5
minutes at 4°C to pellet nanoparticle-containing cells.
Pellets were stored for quantitation of inorganic
material (ICP-MS) or drug (UPLC-UV/Vis), as
detailed in supplemental materials.
177LuEuS

biodistribution

SPECT-CT imaging was performed on mice to
assess the in vivo biodistribution of 177LuEuS particles.
Each animal was dosed by tail-vein injection with ~
500 μCi of 177LuEuS (volume of injection: 170 μL) plus
45 mg/kg NRPV (volume of injection: 100 μL). Images
http://www.ntno.org
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were acquired at 6, 12, 24, 48, and 120 hours post
injection using a SPECT-CT system (Flex Triumph,
TriFoil Imaging, Northridge, CA, USA) fitted with a
five pinhole (1.0 mm per pinhole) collimator. CT
images were acquired using 360 projections over 360°
with an X-ray tube current of 140 mA and voltage of
75 kilovoltage peak (kVp) at a magnification of 2.0
(field of view = 59.2 mm2). Immediately after, SPECT
image acquisition was performed with the following
parameters: 64 projections at 15 seconds per
projection over 360° using a radius of rotation of 48
mm (field of view = 59 mm2). Co-registration of
anatomical CT images and functional SPECT was
performed by 3D visualization and analysis software,
VivoQuant 3.5 (Invicro Boston, MA, USA). Regions of
interest (ROIs) were drawn over various organs and
radioactivity content and organ volumes were
determined and used to calculate counts per cubic
millimeter (mm3). Mice were sacrificed 5 days
post-injection. Heart, lungs, liver, pancreas, stomach,
spleen, small intestine, large intestine, kidneys,
bladder, lymph nodes, muscle, bone, brain, testes,
injection site (tail) and blood were collected, weighed,
and analyzed for radioactivity using gamma
scintillation
spectrometry
(ORTEC
NaI(Ti)
Scintillation Radiation Detector, Ametek, Oak Ridge,
TN, USA). Additionally, animals were individually
caged so that excreted signal could be measured from
the bedding. Signal measured was back calculated to
the injection time to account for the radioactive decay
of 177Lu (t1/2 = 6.64 days). The signal from each tissue
was normalized to the sum of total counts from all
sources and then divided by the weight of the organ
to obtain % injected dose (ID)/g for each tissue.

MRI relaxivity measures
EuS particle phantoms for MRI measures were
prepared as previously reported [20]. MRI data were
acquired on a 7T/16 cm Bruker PharmaScan MRI
system (Bruker; Ettlingen, Germany). For T2 map
measurements, CPMG (Carr Purcell Meiboom Gill
sequence) phase-cycled 3-dimensional multi-echo
sequence data was acquired with 250 ms repetition
time, 48 echoes (echo times TEn = n X 2.618; n =
1,…,48), 128 × 128 × 64 acquisition matrix, 70 × 64.76 ×
42.38 mm FOV, one average, for a total scan time of 34
min.

Animal MRI
Animal MRI was performed on a 7T/16 cm
Bruker PharmaScan MRI system. Mice were
anesthetized with isoflurane in 100% oxygen and
maintained at 40-80 breaths per minute. Animals were
scanned by MRI prior to or after dosing with EuS (17
mg/kg, tail vein injection). T2-relaxtion maps were
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generated using a CPMG phase-cycled multi-echo
multi-slice sequence. Data were acquired with 3000
ms repetition time, 50 echoes (echo times TEn = n × 10
ms; n = 1), 256 × 128 acquisition matrix, 25 × 25 mm
FOV, slice thickness = 0.5 mm, 2 averages, for a total
scan time of 13 min. T2 signal in liver, spleen, and
kidneys was quantified by densitometry of ROI
pixilation in ImageJ v1.51m9 (National Institutes of
Health, USA) [21] and converted to ΔR2 as
1000/(T2post-treatment – T2pre-treatment).

Statistical analyses
Linear regressions and statistics were calculated
in GraphPad Prism v7.0 (La Jolla, CA) as described in
the figure legends. Data are depicted as mean ±
standard error of the mean (SEM) of biological
triplicates. Statistical significance was measure by
two-way ANOVA with Bonferroni corrections for
multiple comparisons.

Results
Synthesis and characterization of radiolabeled
EuS (177LuEuS) nanoparticles
Intrinsic “chelator-free” and non-leachable
radiolabeled europium sulfide (177LuEuS) was first
synthesized by solvothermal precipitation of
europium
(III)
chloride
hexahydrate
and
1-decanethiol in the presence of oleic acid, oleylamine
and octadecene with 177LuCl3 at 290°C (Figure 1A).
Parallel reactions were performed without 177LuCl3 to
enable non-radioactive experiments. Lipid coatings
containing
L-α-phosphatidylcholine
and
DSPE-PEG2000 were used to make biocompatible lipid
coatings for EuS particles. Transmission electron
microscopy (TEM) revealed that EuS nanocrystals had
rod shapes of 25 nm in diameter by ~ 350 nm in length
(Figure 1B). These approximate the 250 nm and 350
nm hydrodynamic diameters of NRPV, and RPV
prodrug formulations (NM3RPV) as described
previously [19]. High resolution (HR)-TEM images
(Figures 1C-E) show the lattice fringes with spacings
of 0.36-0.37 nm. High-angle annular dark-field
scanning TEM (HAADF-STEM) illustrates europium
(Eu; red) and sulfur (S; green) as an approximate
70%:30% composition (Figure 1F).
The X-ray diffraction (XRD) shown in Figure 1G
reveals that all peaks are indexed into a cubic crystal
and reconfirmed with the JCPDS file for Eu and S or
bulk EuS (JCPDS file numbers; 01-073-6349;26-1419;
05-001-0200; 04-007-2069). The XRD peaks of 14.5°,
15.0°, 17.0°, 25.0°, 27.3°, 29.35°, 31.6°, 34.7°, 40.5°,
41.85°, 43.8°, 46.63° and 50.9° at 2θ are typical
indications for face-centered cubic planes of EuS
crystal structure. For example, space group (111 = hkl)
http://www.ntno.org
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lattice spacing approximate 3.6 Å = 0.36 nm,
corresponding to 25.0° in 2θ and 0.36 nm spacing
obtained through HR-TEM (Figures 1C-E). The
energy dispersive X-ray spectroscopy (EDX) analysis
demonstrated “europium” and “sulfur” signals were
detected in the EuS nanoprobes (Figure 1H). Results
cumulatively illustrate successful synthesis of
rod-shaped nanoprobes whose elemental core
constituents are readily detectable after formulation.

Multimodal trackability of EuS Nanoparticles
To ascertain the potential of EuS as surrogates
for NRPV tracking in vivo, the nanoprobes were tested
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for compatibility with a range of bioimaging
modalities. Fluorescence provides a sensitive means
of detection across short distances. Fluorescent blue
spectra for EuS revealed maximal excitation and
emission wavelengths at 410 nm and 510 nm,
respectively (Figure 2A). EuS fluorescence is due to
electron transitions from the 4f7 ground state to 4f6
5d1 excited state (Eu(II)) [22]. Similarly observed
results from europium-containing nanotubes have
been attributed to a +2-oxidation state that yields blue
light upon UV wavelength excitation [23].

Figure 1. Synthesis and characterization of EuS particles. (A) Synthesis scheme of EuS particles. 1-Dodecanethiol served as a reducing agent plus sulfur precursor; the vial
shows particle fluorescence. (B) Low-resolution TEM image of EuS is illustrated. The EuS dimensions were approximately 25 nm in diameter by ~ 350-500 nm in length. (C)
HR-TEM images of a single EuS particle with lattice planes of 0.37 nm, corresponding with XRD data. (D-E) The selected area electron diffraction (SAED) pattern of EuS show
characteristic interplanar spacing of the EuS single crystal structure. (F) The europium (red) and sulfur (green) element STEM mapping showed element localization within the
particles by corresponding high-angle annular dark-field electron microscopy. (G) XRD patterns, correlating with HR-TEM lattice pattern and SAED data sets, confirmed the
particles’ structural configurations. (H) Chemical composition of EuS particles assessed by EDX qualitatively demonstrated the particle elements.

http://www.ntno.org
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Figure 2. Intrinsic tracking properties of europium sulfide (EuS) nanoprobes. (A) Fluorescence spectra of resuspended EuS at λmax 410 nm excitation. (B) R2
relaxation rate (inverse T2 value) was determined using serial dilution of EuS phantom particles in agar matrix. (C-F) Integrity of 177Lu intrinsic doping in EuS nanoparticles was
determined by dosimetry. (C-D) Stability was calculated by normalizing radioactivity of experimental pellets against those of control. (E-F) The half-lives of 177LuEuS were
calculated using one-phase decay algorithms of radiation levels across times using GraphPad Prism v7.0.

Intact NRPV likewise emits fluorescence, albeit
at a shorter wavelength (385 nm), resulting from
aggregation induced emission [24]. The MRI
compatibility of EuS was also determined as a means
of quantifying particle accumulation at different
tissue depths. At issue lies the propensity of f  d
transition block electrons to preferentially oxidize
Eu2+ to Eu3+, whose MRI relaxivity is short-lived [25].
The T2-weighted relaxivity constant of EuS
nanoprobes measured 0.5177 ppm/second and
showed strong linear correlation with europium
concentration (Figure 2B). High T2-weighted
relaxivity paired with blue wavelength emission
suggests coordinated electron stability conferred to
europium by sulfide atoms. Finally, gamma-ray
emitting 177Lu was intrinsically doped into the cores of
EuS nanoprobes to provide a final means of sensitive
biotracking via SPECT-CT. The particle stability and

half-life of 177LuEuS was found to be ~3.4 days under
physiological conditions (37oC in serum matrix),
which represents a 45-50% reduction from the
half-lives of control-incubated sample (6.2 days) and
native 177Lu (6.7 days) (Figures 2C-F). The
radioactivity profile of 177LuEuS indicates that the
nanoprobes are compatible with SPECT-CT imaging
over a short duration.

Endocytic Pathways of EuS Nanoparticle
Uptake
We next examined the propensity for HIV-1
infectible CD4+ T cells and monocyte-derived
macrophages
(MDM)
to
endocytose
EuS
nanoparticles. A non-cytotoxic concentration of 10
ppm Eu153 was determined by mitochondrial vitality
assay over 24 hours in CEM-ss CD4+ T cells (Figure
3A). A time course of EuS nanoparticle uptake in
http://www.ntno.org
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CEM-ss cells revealed 52% uptake of 10 ppm Eu153
treatment by 24 hours (Figure 3B). The one-site
saturation kinetic modeling of EuS uptake indicates
delayed nanoparticle entry that becomes apparent
between 4 and 8 hours post-treatment. To investigate
a possible mechanism for EuS nanoprobe endocytosis
by CD4+ T cells, a 24-hour uptake experiment was
repeated in the presence of chemical inhibitors.
Clathrin, dynamin, or actin related protein 2/3 (Arp
2/3) complexes were blocked with Pitstop2 [26],
Dynasore [27], or CK666 [28], respectively. Dynamin
blockade with Dynasore elicited reductions in NRPV
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(50%) and EuS (35%) uptake (Figure 3C-D).
Notably, clathrin inhibition by Pitstop2 also
attenuated NRPV accumulation in CD4+ T cells
(Figure 3C). The reduction of EuS uptake with
dynamin inhibition (Figure 3D) paired with the
appearance of endocytic pits by TEM (Figure 3E)
suggests that caveolin rather than clathrin or actin line
the cytoplasmic surface of CD4+ lymphocyte cellular
invaginations [29].
Macrophages, which serve as long-term depots
for nanoformulated antiretroviral prodrugs, were
likewise assayed for phagocytosis of EuS. MTT

Figure 3. Dynamin-mediated endocytosis of EuS nanoparticles by CEM-ss T cells. (A) EuS cytotoxity in CEM-ss T cells after 24-hour incubation was determined by
MTT assay. (B) Time course of EuS uptake when treated at 10 ppm Eu153 was measured by ICP-MS. Saturation kinetic curve was fitted to experimental data using 1-site saturation
curve in GraphPad Prism v7.0. (C-D) The mechanisms of NRPV and EuS nanoparticle uptake were assessed by pre-treating with clathrin-inhibitor (Pitstop2, 30 µM),
dynamin/caveolin-inhibitor (Dynasore, 100 µM), or actin-mediated active transport inhibitor (CK666, 4 µM). (E) Transmission electron micrographs of CEM-ss T cells in the
absence (left) or presence (center) of EuS. Far right micrograph (inset of center) depicts nanoparticle within endocytic pit. Bar graphs depict mean ± SEM of three biological
replicates. Statistical differences were determined using two-way ANOVA between groups with a Bonferroni's post hoc-test to correct for multiple comparisons. *p < 0.05; ns:
non-significant.

http://www.ntno.org
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assessment indicated no decline in mitochondrial
vitality at concentrations up to 100 ppm Eu153 (Figure
4A). MDM displayed maximal uptake between 2-4
hours post treatment, with 28% of the added EuS
particles taken up by the cells by 4 hours (Figure 4B).
These levels approximate the 10% NRPV uptake
reported in MDM previously [24]. Co-treatment with
Dynasore significantly reduced EuS uptake in MDM
by 40% (Figure 4C). Together, these data point to
enhanced and rapid uptake of EuS by macrophages in
a caveolin-dependent manner.

EuS nanoparticle real time biodistribution
Intrinsically doped 177LuEuS particles were
assessed for their acute biodistribution upon
intravenous (IV; via tail-vein) injection. To accelerate
redistribution from muscle depots formed by longacting antiretroviral intramuscular administration,
mice were dosed sequentially with NRPV (45 mg/kg)
followed by EuS nanorods (~500 μCi 177LuEuS/mouse
or 17 mg Eu153/kg) via tail-vein injection. Bioimaging
by SPECT-CT revealed an initial accumulation of
nanoprobes in lungs by 24 hours (Figure 5A-B). This
finding was unexpected but indicative that the
300-500 nm length of our particles likely caused them
to become entrapped in pulmonary capillaries during
IV administration. By 48 hours, 177LuEuS were readily
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imaged in known HIV-1 anatomic reservoirs
including spleen, liver, lungs, colon, and lymph
nodes. SPECT-CT performed 5 days post-dosing
illustrated the highest accumulation of 177LuEuS in
spleen.
An extended 30-day time course was used to
examine EuS nanoprobe biodistribution via MRI.
T2-weighted images revealed initial accumulation of
EuS in liver two days post dosing, with significant
redistribution to spleen between days 10 and 30
(Figure 5C). The limitations of T2 contrast nanoprobes
was observed by the lack of enhancement in lungs,
ileum, colon, lymph nodes and brain. These results
highlight the value in designing rod-shaped
nanoparticles for trafficking payloads to the spleen, a
known secondary lymphoid organ.

EuS accumulation in organs approximates
NRPV biodistribution
Comparative analyses were performed to
determine the utility of EuS nanoprobes as predictive
biotrackers for NRPV distribution. Organs collected at
sacrifice 5 days post-dosing revealed greatest
accumulation of RPV in spleen (313 ng/g tissue), lung
(257 ng/g tissue), lymph nodes (174 ng/g tissue), and
liver (78 ng/g tissue) (Figure 6A).

Figure 4. EuS uptake in human monocyte-derived macrophages (MDM). (A) EuS cytotoxicity in MDM after 24-hour incubation was determined by MTT assay. (B)
Time course of EuS uptake of cells treated with 100 ppm Eu153 over 24 hours as measured by UPLC-TUV. The saturation kinetic curve was fitted to experimental data using 1-site
saturation curve in GraphPad Prism v7.0. (C) The mechanism of nanoparticle uptake was assessed by pre-treating with Pitstop (30 µM), Dynasore (100 µM), or CK666 (4 µM)
endocytic inhibitors. Graphs depict mean ± standard error of the mean (SEM) of three biological replicates. Statistical differences were determined using two-way ANOVA
between groups with a Bonferroni's post hoc-test to correct for multiple comparisons. *p < 0.05; ns: non-significant.
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Figure 5. Europium-sulfide (EuS) nanoparticles redistribute to spleen. Male Balb/c mice (n = 5) were tail vein injected with ~ 500 µCi 177LuEuS nanoparticles (17 mg/kg
europium-153) or EuS (17 mg/kg europium-153) plus NRPV (45 mg/kg). (A) SPECT-CT images and (B) signal concentrations in ROIs were processed using VivoQuant v3.5
(Invicro Imaging Software) based on anatomy observed in plain CT. (C) Differences in R2 relaxivity after dosing (ΔR2) based on densitometry in ROIs drawn in ImageJ were
calculated. Plots represent averages ± SEM.

Europium-153
concentrations
were
also
observed to be highest in the spleen (428 μg/g tissue),
lung (525 μg/g tissue), and liver (73 μg/g tissue) by
day 5 as measured by ICP-MS (Figure 6B). Parallel
findings were observed using gamma-ray scintillation
counting, which reflects 177Lu content (Figure 6C).
Lower metal contents observed in lymph nodes at day
5, as compared to RPV, could result from variability in
the sizes and locations from which lymph nodes were
collected at the time of harvest.
Mass spectrometry quantitation for drug and
metals performed at day 30 post-dosing revealed
similar accumulations to those found at day 5. In
particular, RPV was readily detectable in spleen (33
ng/g tissue), liver (9.3 ng/g tissue), and lungs (5 ng/g
tissue) (Figure 7A). Europium-153 measured 1409
μg/g tissue in spleen, 223 μg/g tissue in liver, and 95
μg/g tissue in lungs (Figure 7B). Replicate values for
NRPV and EuS in colon and brain approached assay

detection limits. The comparable distribution of both
particles to macrophage rich organs suggests
phagocytic processes are vital in determining the
biodistribution of theranostics.
Pearson correlations validated the significance of
these trends at early and late timepoints. Spleens from
dual-treated mice demonstrated a correlation between
RPV and europium-153 concentrations (p = 0.0498;
Figure 6D). This may relate to differences in organ
perfusion or overall animal health in the context of
dosing with radioactive materials. Meta-analysis from
terminal sacrifice also displayed a significant
correlation (p < 0.0001) between rilpivirine and
europium-153 present in each organ (Figure 7C). As
the high accumulation of both EuS and NRPV in
spleen anchored this trend, it is possible that the
utility of EuS in predicting drug content deposits in
organs that serve as minor depots for ART is limited.
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Figure 6. Quantitative analysis of RPV and EuS in mouse tissues 5 days post-dosing. (A) NRPV drug concentration was measured in various tissues by UPLC-MS. (B)
Europium-153 concentration was quantitated by ICP-MS. (C) Gamma-ray emission from collected tissues was measured after briefing radioactive decay by scintillation counting.
(C) Raw radioactivity was divided by total radioactivity in all tissue measured per animal, giving percent injected dose, which was further normalized against tissue weight (% ID/g).
(D) Pearson correlation between NRPV drug concentration values and europium-153 was determined in day 5 spleen samples.

Figure 7. EuS correlates with NRPV biodistribution 30 days post-dosing. (A) NRPV drug concentration was measured in various tissues by UPLC-MS/MS. (B)
Europium-153 concentration was quantitated by ICP-MS. (C) Day-30 Pearson correlation was calculated between average RPV drug concentration and europium-153
concentration for each organ.
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Discussion
Long-acting antiretroviral nanoformulations
serve to improve therapeutic outcomes for treatment
of HIV-1 infection and for prevention through PrEP.
We posit that the development of such therapeutics
can be accelerated through nanotheranostics. Here,
defining delivery of drugs to cell and tissue reservoirs
could lead to improved viral suppression, reduced
transmission
and
CRISPR-associated
HIV-1
elimination. As a first step to achieve these goals we
investigated the delivery of the newly United States
Food and Drug Administration approved long acting
antiretrovirals. This includes RPV, which with CAB,
has demonstrated non-inferiority as part of HIV-1
maintenance therapy [3]. Given that long-acting ART
injections are not indicated for induction therapy, we
sought to characterize RPV nanoparticles’ ability to
reach viral reservoir target sites. Sensitive nanoprobes
with bioimaging capabilities offer a surrogate means
to trace antiretroviral biodistribution while reducing
the cost, labor, and time otherwise required to survey
drug concentrations at tissues of interest. Herein, we
validated the utility of EuS nanoparticles as mimetics
for NRPV cellular uptake and biodistribution.
Although macrophages readily phagocytose
antiretroviral nanoparticles, ART efficacy is in part a
property of cellular uptake. Prior works revealed that
rod-shape, use of poloxamer excipients, and surface
decoration with folate, all modestly enhance ART
nanoparticle uptake by macrophages [30, 31].
Theranostics have recapitulated these findings [16,
20]. Here we present dynamin/caveolin as a primary
endocytic pathway for nanoparticle entry into MP,
distinct from previously reported clathrin-mediated
endosomal
trafficking
of
protease-inhibitor
nanoparticles [32, 33]. Nanoformulated drugs
accumulate in late endosomes where HIV-1 virions
are present in high abundance [33, 34]. Antiretroviral
prodrug nanoformulations are also present in high
abundance within late- and recycling endosomes [35,
36]. We postulate that while nanoformulated
antiretrovirals and long-acting prodrugs both meet
their targets in endosomes, prodrugs are hydrolyzed
to their active forms under increasingly acidic late
endosomal and lysosomal microenvironments [37]
whereas native ART become degraded. HIV-1 and
antiretroviral drug nanoparticles employ recycling
endosomes for sustained release from cells [38].
Accordingly, all therapeutic nanoparticles for HIV-1
treatment should be engineered to withstand
acidification in late endosomes.
An alternative to macrophage-mediated delivery
rests in the direct uptake of particles by CD4+ T cells.
As dynamin but not clathrin blockade significantly
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impeded EuS and NRPV uptake, we conclude that
CD4+ T cells endocytose nanocrystals in caveolincoated pits which operate in tandem with dynamin
“pinching” of invaginated surfaces during endocytic
vesicle formation. This finding accords with other
studies that describe dynamin-2 as critical in CD4+ T
lymphocyte endocytosis of T cell receptors [39] and
HIV-1 [40]. Dynamin-2 enables HIV-1 transmission
between adjacent T cells [40] and triggers appropriate
clonal expansion via mTOR-cMyc signal cascades
when TCR encounters cognate antigen [39]. As such,
dynamin likely serves as an important cytoskeletal
protein involved in transmission of vesicle-bound
materials within its limited cytoplasm. Inclusion of
rare earth metals, like europium, in therapeutic
nanoparticles would confer the ability to track its
migration through T cells’ endosomal network via
fluorescence.
Theranostic drug particles play an essential role
in tracking therapeutic cargo in vivo. The rod shape
and size of EuS matches the morphology of NRPV but
maintains inherent fluorescent and magnetic
properties. EuS was modified with lipids and
transformed from lipophobic to lipophilic to expand
tracking. The simplified EuS design, which eliminates
the need for transition metals to complex with
europium,
conferred
predictive
multimodal
trackability over a month. Unlike previous
nanoprobes bearing cobalt-ferrite cores [14, 16], sulfur
atoms sufficiently stabilize the europium (II)
oxidation state. This enhanced its blue-wavelength
fluorescence and T2-weighted contrast capabilities.
Sulfur is a preferred coordinate binding partner to
other inorganic elements as a result of its high
biocompatibility [41, 42], antioxidant capacity [43],
and low cost. Europium-153 concentrations correlated
with RPV content in macrophage rich organs
including spleen, liver, and lungs. Accordingly, EuS
proved useful as a surrogate for RPV concentration
for up to 30 days, particularly in splenic tissues. Noninvasive SPECT-CT and MRI revealed nanoprobe
redistribution from lung to macrophage-rich tissues
including liver and spleen. Our prior studies showed
detectable RPV levels in liver, spleen, lymph nodes,
and gut for up to 56-days following intramuscular
injection of NRPV [19]. The perfusion of alveolar
macrophages in lung, Kupffer cells in liver, and
marginal zone macrophages in spleen likely underlie
the biodistribution of EuS and NRPV. Although EuS
were observed in lower quantities within lymph
nodes as compared to NRPV, EuS is still likely to be
present in the splenic periarteriolar lymphoid sheath
(PALS) that is rich in CD4+ T cells [44]. High density
177Lu signal emanating from the spleen at day 5 and
T2-weighted contrast at day 30 may also indicate that
http://www.ntno.org
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marginal zone- and red-pulp macrophages readily
engulf EuS nanoprobes. In summary, EuS nanoprobes
whose size and shape approximates that of NRPV
display similar trafficking to spleen.
Although similarities were found between
NRPV and EuS accumulation in spleen, liver and lung
it is worth noting significant biodistribution
disparities exist in other organs. Prior studies have
demonstrated high RPV levels in kidney and gut
exceeding those of spleen and liver 56 days after
intramuscular dosing with poloxamer-encapsulated
NRPV [19]. By contrast, intravenous co-dosing of
bismuth-sulfate nanorods (BSNRs) with NRPV
favored drug deposition in spleen and lymph node
rather than kidney by four weeks post-injection [15].
Our findings recapitulate the notion that IV
administration of NRPV enhances deposition in
reticuloendothelial organs rather than those that
facilitate drug excretion. Differences in particle
biodistribution in non-lymphoid organs likely results
from NRPV being nanoformulated with a poloxamer
surfactant whereas EuS nanoprobes are encapsulated
in cholesterol-based lipids. Future experiments will
ensure that nanotheranostic compositions and route
of administration is synchronized with those of
nanoformulated antiretrovirals.
EuS nanoprobe biotracking reveals three
therapeutic parameters. First, nanoparticles should be
made with long-axis diameters below ~ 350 nm. This
will serve to ensure that any defined therapeutics do
not become entrapped in pulmonary capillaries that
not only blunt systemic dissemination but could pose
risk of pulmonary and cardiac failure. On balance,
nanoparticles size must exceed 24 nm to avert
inducing disseminated intravascular coagulation [45].
Second, lipid components present in the particle’s
protective shell, core or complexed with therapeutic
payloads should be of sufficient hydrophobicity to
permeate lymph nodes. Reaching lymph nodes,
where latently-infected memory CD4+ T cells are
predominantly located, is critical for any therapeutic
strategy developed to sterilize virus in an infected
host [46]. Third, any newly designed theranostic
particles
must
mirror
the
physicochemical
characteristics of antiretroviral prodrug nanocrystals,
which show enhanced cell uptake and the slow ester
hydrolysis of hydrocarbon promoieties, to parallel
biodistribution patterns that now enable 90%
inhibitory concentrations in plasma from months to
up to one year [8].
Future investigations are planned to facilitate
bench to bedside use of the EuS nanoprobes. First,
intramuscular injection of EuS is required to simulate
the route of long-acting antiretroviral administrations.
Second, the utility of europium-153 fluorescence by
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confocal microscopy and flow cytometry must be
employed to assess EuS uptake in divergent cell types.
Third, serum enzyme profiles and histological
assessments will need to be tested in order to
determine potential EuS toxicity. Finally, the DSPEPEG2000 lipid shell can be complexed to targeting
ligands such as folic acid and tuftsin to evaluate
whether surface modification improves particle
delivery to lymphoid organs and the brain.

Conclusions
EuS nanoprobes retain multimodal molecular
imaging potential for delivery of rod-shaped
therapeutic nanomaterials to HIV-1 reservoir sites.
Advantages to this composition include reduced
requirement for transition metals in particle synthesis,
which confers improved biocompatibility to EuS and
lowers production cost. Taken together, this
technology provides a platform to accelerate the pace
of nanoformulated ART development and maximize
delivery of therapeutics to viral cell and tissue
reservoirs.
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